A reversible carnitine palmitoyltransferase (CPT1) inhibitor offsets the proliferation of chronic lymphocytic leukemia cells

Haematologica. 2018 Nov;103(11):e531-e536. doi: 10.3324/haematol.2017.175414. Epub 2018 Jun 21.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • A549 Cells
  • Carnitine O-Palmitoyltransferase / antagonists & inhibitors*
  • Carnitine O-Palmitoyltransferase / genetics
  • Carnitine O-Palmitoyltransferase / metabolism
  • Cell Proliferation / drug effects*
  • Enzyme Inhibitors / pharmacology*
  • HCT116 Cells
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell* / enzymology
  • Leukemia, Lymphocytic, Chronic, B-Cell* / genetics
  • Leukemia, Lymphocytic, Chronic, B-Cell* / pathology
  • MCF-7 Cells
  • Neoplasm Proteins / antagonists & inhibitors*
  • Neoplasm Proteins / genetics
  • Neoplasm Proteins / metabolism
  • PC-3 Cells

Substances

  • Enzyme Inhibitors
  • Neoplasm Proteins
  • Carnitine O-Palmitoyltransferase